All Stories

  1. Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation

    Article • Journal of Alzheimer s Disease, August 2022, IOS Press

    Lucilla Parnetti

  2. Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies

    Article • Future Neurology, September 2018, Future Medicine

    Lucilla Parnetti

  3. Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment

    Article • Journal of Alzheimer s Disease, June 2018, IOS Press

    Lucilla Parnetti

  4. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis

    Article • Movement Disorders, September 2017, Wiley

    Dr Iosief Abraha, Paolo Eusebi, Lucilla Parnetti, david giannandrea

  5. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients

    Article • Movement Disorders, August 2017, Wiley

    Dr Nicola Tambasco, Paolo Eusebi, Lucilla Parnetti, Dr. Nicola Tambasco

  6. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease

    Article • Expert Review of Molecular Diagnostics, June 2017, Taylor & Francis

    Paolo Eusebi, Lucilla Parnetti

  7. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

    Article • Movement Disorders, October 2016, Wiley

    Paolo Eusebi, Lucilla Parnetti

  8. New CSF biomarkers on the block

    Article • EMBO Molecular Medicine, September 2016, EMBO

    Lucilla Parnetti

  9. Free water elimination improves test–retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects

    Article • Human Brain Mapping, August 2016, Wiley

    Miss Angela Albi, Lucilla Parnetti

  10. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice

    Article • Movement Disorders, May 2016, Wiley

    Paolo Eusebi, Lucilla Parnetti

  11. Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment

    Article • Movement Disorders, April 2016, Wiley

    Lucilla Parnetti

  12. Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links

    Article • Movement Disorders, February 2016, Wiley

    Lucilla Parnetti

  13. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

    Article • Journal of Neurochemistry, February 2016, Wiley

    Lucilla Parnetti

  14. Lysosomal enzymes in PD: Further evidence is needed

    Article • Movement Disorders, July 2014, Wiley

    Lucilla Parnetti